A targeted salvage therapy with brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients who received autologuos stem cell transplantation (ASCT).
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015